Third-party evaluation confirms safety profile of Philips Stellarex .035″ low-dose drug-coated balloon

NEXT STORY
TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain
PREV STORY
Eurobio Scientific joins the Enternext PEA PME 150 index
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility

author_avatar
NASDAQ Market News

Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45

author_avatar
NASDAQ Market News

FIT Biotech Oy: FIT Biotech Oy converts Convertible Capital Notes into shares and exceeds the authorization granted in the Extraordinary General Meeting on February 6, 2018

FIT Biotech Oy Company release March 21, 2018 at 03:30 PM EET FIT Biotech ...

author_avatar
NASDAQ Market News